Published in Oncogene on May 01, 1993
Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol (1997) 2.40
P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer (2000) 2.35
Li-Fraumeni syndrome--a molecular and clinical review. Br J Cancer (1997) 2.14
Are there low-penetrance TP53 Alleles? evidence from childhood adrenocortical tumors. Am J Hum Genet (1999) 1.57
Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. Am J Hum Genet (1995) 1.46
Two Li-Fraumeni syndrome families with novel germline p53 mutations: loss of the wild-type p53 allele in only 50% of tumours. Br J Cancer (1998) 0.89
p53: a frequent target for genetic abnormalities in lung cancer. Science (1989) 7.51
Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med (1995) 6.77
Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature (1984) 6.23
Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med (1995) 5.98
L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. Nature (1985) 4.66
Widespread occurrence of intermediate-sized filaments of the vimentin-type in cultured cells from diverse vertebrates. Exp Cell Res (1979) 4.61
Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med (1993) 4.28
Early care limitations independently predict mortality after intracerebral hemorrhage. Neurology (2007) 3.73
Differential expression of myc family genes during murine development. Nature (1986) 3.57
Genome-wide survey of protein kinases required for cell cycle progression. Nature (2004) 3.40
Diversity of cytokeratins. Differentiation specific expression of cytokeratin polypeptides in epithelial cells and tissues. J Mol Biol (1981) 3.37
Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res (1998) 3.20
Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. Oncogene (1990) 2.97
Vascular smooth muscle cells differ from other smooth muscle cells: predominance of vimentin filaments and a specific alpha-type actin. Proc Natl Acad Sci U S A (1981) 2.94
Incidence and risk factors for side effects of spinal anesthesia. Anesthesiology (1992) 2.94
p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J (1992) 2.90
Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat Genet (2001) 2.76
p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene (1992) 2.64
Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer. J Clin Oncol (1992) 2.63
Evidence for complement-binding immune complexes in adult coeliac disease, Crohn's disease, and ulcerative colitis. Lancet (1973) 2.60
Differentiation-related patterns of expression of proteins of intermediate-size filaments in tissues and cultured cells. Cold Spring Harb Symp Quant Biol (1982) 2.32
Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res (1999) 2.32
Nitric oxide potentiates hydrogen peroxide-induced killing of Escherichia coli. J Exp Med (1995) 2.14
Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res (2001) 2.12
Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. Cancer Res (1985) 2.12
Palindromic rheumatism. Clinical and serum complement study. Ann Rheum Dis (1977) 2.06
Protein complexes of intermediate-sized filaments: melting of cytokeratin complexes in urea reveals different polypeptide separation characteristics. Proc Natl Acad Sci U S A (1983) 2.05
Complications of percutaneous ethanol ablation. J Ultrasound Med (1998) 2.03
Acute delirium after withdrawal of amantadine in Parkinson's disease. Neurology (1998) 2.00
An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clin Exp Metastasis (2000) 2.00
Cognitive-behavioral therapy to reduce weight concerns improves smoking cessation outcome in weight-concerned women. J Consult Clin Psychol (2001) 1.99
Sonographic and Doppler characteristics of the corpus luteum: can they predict pregnancy outcome? J Ultrasound Med (2001) 1.98
Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther (2011) 1.98
Human small-cell lung cancers show amplification and expression of the N-myc gene. Proc Natl Acad Sci U S A (1986) 1.96
Interdigitating dendritic cell sarcoma. A report of four cases and review of the literature. Am J Clin Pathol (2001) 1.93
Volume-outcome relation for physicians and hospitals performing angioplasty for acute myocardial infarction in New York state. Circulation (2001) 1.91
Evidence for in vivo breakdown of beta-10-globulin in hypocomplementemic glomerulonephritis. J Clin Invest (1967) 1.90
Second malignancies after Ewing's sarcoma: radiation dose-dependency of secondary sarcomas. J Clin Oncol (1996) 1.90
Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst (1991) 1.85
On the spatial spread of rabies among foxes. Proc R Soc Lond B Biol Sci (1986) 1.84
4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J Med Chem (2000) 1.84
Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood (1994) 1.79
Positron emission tomography study of voluntary saccadic eye movements and spatial working memory. J Neurophysiol (1996) 1.78
Formation of cytoskeletal elements during mouse embryogenesis. II. Epithelial differentiation and intermediate-sized filaments in early postimplantation embryos. Differentiation (1981) 1.78
Linkage mapping of dopa-responsive dystonia (DRD) to chromosome 14q. Nat Genet (1993) 1.78
Retinoblastoma--origin from a primitive neuroectodermal cell? Nature (1984) 1.78
Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: a Pediatric Oncology Group study. Ann Neurol (1998) 1.76
Validation of a model of colon cancer progression. J Pathol (2000) 1.76
Dynamic model of differentiation in Ewing's sarcoma cells. Comparative analysis of morphologic, immunocytochemical, and oncogene expression parameters. Lab Invest (1992) 1.75
Detection of immune complexes by a new assay, the polyethylene glycol precipitation-complement consumption test (PEG-CC). Clin Exp Immunol (1979) 1.74
Solid extratesticular masses evaluated with sonography: pathologic correlation. Radiology (1997) 1.74
Electrophysiological study of cardiovascular neurons in the rostral ventrolateral medulla in rats. Circ Res (1985) 1.73
Immunoglobulin V/J recombination is accompanied by deletion of joining site and variable region segments. Proc Natl Acad Sci U S A (1980) 1.72
Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res (1992) 1.72
Staging of advanced ovarian cancer: comparison of imaging modalities--report from the Radiological Diagnostic Oncology Group. Radiology (2000) 1.70
Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial. J Infect Dis (2007) 1.70
Long-term follow-up of Ewing's sarcoma of bone treated with combined modality therapy. Int J Radiat Oncol Biol Phys (1991) 1.70
In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2. Cancer Res (1994) 1.69
Myogenin is a specific marker for rhabdomyosarcoma: an immunohistochemical study in paraffin-embedded tissues. Mod Pathol (2000) 1.68
Beta-endorphin concentrations in the peripheral blood mononuclear cells of migraine and tension-type headache patients. Cephalalgia (1992) 1.68
Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res (2000) 1.64
Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene (1992) 1.63
Detection of a cytokeratin determinant common to diverse epithelial cells by a broadly cross-reacting monoclonal antibody. EMBO J (1982) 1.63
An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. Ann Oncol (2012) 1.63
Bioterrorism preparedness and local public health agencies: building response capacity. Public Health Rep (2000) 1.62
The in vivo behaviour of complement-coated red cells: studies in C6-deficient, C3-depleted and normal rabbits. Clin Exp Immunol (1970) 1.60
The behaviour of complement and platelets in lethal endotoxin shock in rabbits. Int Arch Allergy Appl Immunol (1973) 1.60
Antihaemophilic globulin: preparation by an improved cryoprecipitation method and clinical use. Br Med J (1967) 1.60
Telomerase activity in precancerous hepatic nodules. Cancer (1998) 1.59
The frequency and clinical significance of specific IgE to both wasp (Vespula) and honey-bee (Apis) venoms in the same patient. Clin Exp Allergy (1998) 1.55
Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer? Br J Cancer (2007) 1.55
Antibodies to the major insoluble milk fat globule membrane-associated protein: specific location in apical regions of lactating epithelial cells. J Cell Biol (1981) 1.55
Inflammatory pseudotumor of the lung in adults: radiographic and clinicopathological analysis. Ann Thorac Surg (1989) 1.53
Isolation and characterization of desmosome-associated tonofilaments from rat intestinal brush border. J Cell Biol (1981) 1.52
Post-transplant lymphoproliferative disease in children. Pediatr Transplant (2001) 1.51
Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J Natl Cancer Inst (1993) 1.50
Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol (1987) 1.50
Cbl-b-dependent coordinated degradation of the epidermal growth factor receptor signaling complex. J Biol Chem (2001) 1.50
Morbidity and mortality in cirrhotic patients undergoing anesthesia and surgery. Anesthesiology (1999) 1.49
Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther (2000) 1.49
Transvenous left ventricular lead implantation with the EASYTRAK lead system: the European experience. Am J Cardiol (2000) 1.48
Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res (1999) 1.47
Serum antibodies to oxidized low-density lipoprotein and ceroid in chronic periaortitis. Arch Pathol Lab Med (1990) 1.47
Dose responses for adaption to low doses of (60)Co gamma rays and (3)H beta particles in normal human fibroblasts. Radiat Res (2002) 1.45
Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. Proc Natl Acad Sci U S A (1994) 1.44
myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course. J Clin Invest (1987) 1.43
Immunohistochemical and ultrastructural localization of leptin and leptin receptor in human white adipose tissue and differentiating human adipose cells in primary culture. Diabetes (2000) 1.43
Re: Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1999) 1.42
Minimally invasive coronary bypass for protected left main coronary stenosis angioplasty. Ann Thorac Surg (1997) 1.42
Pulmonary periarterial inflammation in fatal asthma. Clin Exp Allergy (2009) 1.42